Published in Biotech Business Week, August 22nd, 2005
BLVR is intended to reduce lung volume by delivering proprietary pharmaceutical solutions that form a biodegradable gel to treatment sites within the lung through a standard bronchoscopic procedure. Aeris believes that BLVR has the potential to provide clinical benefits similar to those of lung volume reduction surgery while avoiding the extended recovery period...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.